Companies eye slice of age-related macular degeneration market

Article Abstract:

Lucentis, which is made by S. San Francisco-based Genentech, is the first approved treatment in an age-related macular degeneration. Experts claim that Lucentis will likely dominate the market till its competitors, OSI Pharmaceuticals and QLT, make their entry in the market. Although Lucentis is one step ahead of competitors, it has some drawbacks and industry insiders believe that there is still some room on the market for new products.

United States, Product development, Government regulation, Drug therapy, Licensing, certification and accreditation, Macular degeneration, Lucentis (Medication)

---

Biotech entrepreneur, educate thyself!

Article Abstract:

The dual-degree programs in biotech and business are popping around the world, and the first batch of students to enroll in them are graduating now. Some of the recent graduates who have started their own companies state that these programs help, but are quickly to point that entrepreneurs are born, not taught.

United Kingdom, Education, Study and teaching, Biotechnology, Alumni, Business education

---

Industry waits for fallout from Cabilly

Article Abstract:

The monoclonal antibody firms are mulling over options to avoid royalty payments and the US Patent and Trademark Office rejected their agreement with Genentech as Cabilly II . The issue is likely to be resolved over a decade and the patent is expected to be invalidated in the end.

Alliances, partnerships, Patents & copyrights, Licensing/Sales Agreements, Licensing agreements, Intellectual property, Company licensing agreement, United States. Patent and Trademark Office

Similar abstracts:

• Abstracts: Air Force needs 'clear picture' of tanker needs: GAO. AF general: Raptor has deterrent value. Analyst assails proposal to kill Air Force variant of JSF
• Abstracts: Accountancy's monthly round-up of the latest tax developments: Trust modernisation. part 2 Narrowing the trust gaponid economic condu
• Abstracts: Consumer attitudes toward marketing strategies over the adult life span. Reflection on contemporary issues in relationship marketing: evidence from a longitudinal case study in the building materials industry
• Abstracts: Einer Elhauge. Cancer Pathways' target not validated by clinical results. Genentech discloses safety concerns over Avastin

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.